Plexa ICD Lead Registry

September 18, 2020 updated by: Biotronik, Inc.
The purpose of this registry is to confirm the long-term safety and reliability of BIOTRONIK's Plexa ICD lead.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
901

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Fairhope, Alabama, United States, 36532
        • Thomas Hospital Research Office
    • California
      • Los Angeles, California, United States, 90048
        • Jeffrey S Goodman MD
      • Rancho Mirage, California, United States, 92270
        • Eisenhower Desert Cardiology
    • Florida
      • Orlando, Florida, United States, 32803
        • Florida Hospital
      • Tampa, Florida, United States, 33613
        • Advent Health Tampa
    • Illinois
      • Alton, Illinois, United States, 62002
        • St. Louis Cardiology Consultants
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa Hospitals and Clinics
    • Kansas
      • Wichita, Kansas, United States, 67205
        • Heartland Cardiology
    • Kentucky
      • Owensboro, Kentucky, United States, 42303
        • Research Integrity LLC
    • Maine
      • Bangor, Maine, United States, 04401
        • Northern Light Cardiology
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan
      • Wyoming, Michigan, United States, 49519
        • Metro Health Hospital
      • Ypsilanti, Michigan, United States, 48197
        • Michigan Heart
    • Missouri
      • Saint Louis, Missouri, United States, 63141
        • Mercy Clinic Heart and Vascular
      • Saint Louis, Missouri, United States, 63122
        • St. Louis Heart and Vascular
      • Saint Louis, Missouri, United States, 63128
        • Gateway Cardiovascular Research Center
      • Springfield, Missouri, United States, 65804
        • Mercy Clinic Cardiology
    • Montana
      • Kalispell, Montana, United States, 59901
        • Glacier View Research Institute Cardiology
    • New Jersey
      • Browns Mills, New Jersey, United States, 08015
        • Deborah Heart and Lung Center
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • Novant Health
    • North Dakota
      • Fargo, North Dakota, United States, 58102
        • Sanford Medical Center
    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State Wexner Medical Center
      • Toledo, Ohio, United States, 43608
        • Toledo Cardiology
    • Pennsylvania
      • Newtown, Pennsylvania, United States, 18940
        • The Arrhythmia Institute
    • South Carolina
      • Greenville, South Carolina, United States, 29607
        • Upstate Cardiology
      • Lancaster, South Carolina, United States, 29720
        • Carolina Heart Specialists
      • Rock Hill, South Carolina, United States, 29732
        • Carolina Cardiology Associates
    • Virginia
      • Virginia Beach, Virginia, United States, 23454
        • Cardiovascular Associates Ltd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The subject selected for participation should be from the investigator's general patient population according to the inclusion and exclusion criteria.

Description

Inclusion Criteria:

  • Successfully implanted with a BIOTRONIK ICD or CRT-D compatible system along with the Plexa lead no more than 30 days prior to consent
  • Able to understand the nature of the registry and provide informed consent
  • Available for follow-up visits on a regular basis at the study site for the expected 5 years of follow-up
  • Accepts BIOTRONIK Home Monitoring® concept
  • Age greater than or equal to 18 years

Exclusion Criteria:

  • Enrolled in any investigational cardiac device trial
  • Enrolled in BIOTRONIK's QP ExCELs lead study
  • Planned cardiac surgical procedures or interventional measures within the next 6 months
  • Expected to receive heart transplantation or ventricular assist device within 1 year
  • Life expectancy of less than 1 year
  • Patients reporting pregnancy at the time of enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Subjects Free From Plexa Lead Related Adverse Events
Time Frame: Up to 2.5 years
Evaluate the percentage of subjects without an adverse event related to the Plexa lead through study termination. The endpoint is analyzed as the adverse event free-rate. All protocol defined adverse events that occurred more than 30 days after implant and determined to be related to the Plexa lead plus required invasive intervention to resolve or were related to a lead integrity or clinical performance issue were included. Events meeting this criteria but occurring within 30 days were also included except for lead dislodgement, high pacing threshold, failure to capture, or intermittent capture.
Up to 2.5 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Plexa Lead Safety-Individual Adverse Events
Time Frame: Up to 2.5 years
Evaluate the individual types of adverse events contributing to primary outcome measure 'Percentage of Subjects Free From Plexa Lead Related Adverse Events'
Up to 2.5 years
Pacing Threshold Measurements for the Plexa Lead Through Study Termination
Time Frame: Up to 2.5 years
Pacing threshold measurements at pulse width of 0.4 for the Plexa leads at completed follow-up visits.
Up to 2.5 years
Sensing Measurements for the Plexa Lead Through Study Termination
Time Frame: Up to 2.5 years
Sensing measurements for the Plexa leads at completed follow-up visits.
Up to 2.5 years
Pacing Impedance Measurements for the Plexa Lead Through Study Termination
Time Frame: Up to 2.5 years
Pacing impedance measurements for the Plexa leads at completed follow-up visits.
Up to 2.5 years
Shock Impedance for the Plexa Lead Through Study Termination
Time Frame: Up to 2.5 years
Shock impedance measurements for the Plexa leads at completed follow-up visits.
Up to 2.5 years
Percentage of Subjects Free From Protocol Defined Adverse Events
Time Frame: Up to 2.5 years
Evaluate the percentage of subjects without a protocol defined and clinical event committee adjudicated adverse event, excluding events included in the primary outcome 'Percentage of Subjects Free From Plexa Lead Related Adverse Events', through study termination. Lead dislodgements, high pacing threshold, failure to capture, and intermittent capture related to the Plexa lead that occurred less than or equal to 30 days after lead implant or a lead revision procedure are included here. The endpoint is analyzed as the adverse event free-rate.
Up to 2.5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Biotronik, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 18, 2017

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 27, 2019

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 27, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 31, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 31, 2017

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 6, 2017

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
October 14, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 18, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Plexa Registry

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Implantable Defibrillator User

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings